The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Treating newly diagnosed HL in the UK: practical advice for physicians
Aislinn Macklin-Doherty, MBChB, PhD, The Royal Marsden NHS Foundation Trust, London, UK, shares practical advice for physicians treating relapsed/refractory Hodgkin lymphoma (R/R HL) in the UK. Dr Macklin-Doherty highlights the increasing array of available agents and notes that while advancements in radiation have been significant, there are still high-risk subgroups that require protection from enhanced risks, emphasizing the need for targeted, enhanced early screening. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
